<DOC>
<DOCNO>EP-0640593</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Substituted benzoylguanidines, process for their preparation, their use as medicine or in diagnostic and medicines containing them
</INVENTION-TITLE>
<CLASSIFICATIONS>C07C27900	A61P910	A61P900	A61K314418	A61K314406	C07D207333	C07D21330	A01N102	A61K314402	A61P1500	A61K3140	A61P116	A61P3500	A61P1500	A61P1100	A61P1308	A61P4300	A61K3144	C07D21300	A61K314402	C07D23358	C07D23112	C07D23364	A61K31415	A61P2500	C07D52100	A61K314409	A61P2528	A61K31415	C07D23300	A01N102	A61P1302	A61K314409	A61K314418	A61P100	A61P1312	A61P900	A61K314406	C07D23354	C07D20700	A61P1300	A61K3140	A61P4300	C07D52100	A61P3500	A61P906	A61K3144	A61P310	A61P1100	C07D23100	A61P908	C07D207337	A61P300	C07C27922	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07C	A61P	A61P	A61K	A61K	C07D	C07D	A01N	A61K	A61P	A61K	A61P	A61P	A61P	A61P	A61P	A61P	A61K	C07D	A61K	C07D	C07D	C07D	A61K	A61P	C07D	A61K	A61P	A61K	C07D	A01N	A61P	A61K	A61K	A61P	A61P	A61P	A61K	C07D	C07D	A61P	A61K	A61P	C07D	A61P	A61P	A61K	A61P	A61P	C07D	A61P	C07D	A61P	C07C	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07C279	A61P9	A61P9	A61K31	A61K31	C07D207	C07D213	A01N1	A61K31	A61P15	A61K31	A61P1	A61P35	A61P15	A61P11	A61P13	A61P43	A61K31	C07D213	A61K31	C07D233	C07D231	C07D233	A61K31	A61P25	C07D521	A61K31	A61P25	A61K31	C07D233	A01N1	A61P13	A61K31	A61K31	A61P1	A61P13	A61P9	A61K31	C07D233	C07D207	A61P13	A61K31	A61P43	C07D521	A61P35	A61P9	A61K31	A61P3	A61P11	C07D231	A61P9	C07D207	A61P3	C07C279	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The invention relates to benzoylguanidines of the formula I 
<
IMAGE
>
  where   R(1) is H, Hal, -NO2, -C IDENTICAL N, Xo-(CH2)p-(CF2)q-CF3, R(5)SOm, R(6)-CO-, R(6)R(7)N-CO- or R(6)R(7)N-SO2-, where X is oxygen, S, NR(14), m is zero, 1 or 2, o is zero, 1, p is zero, 1, 2, q is zero, 1, 2, 3, 4, 5, 6, R(5) and R(6) are alk(en)yl, -CnH2n-R(8), CF3, n is zero, 1, 2, 3 or 4, R(8) is cycloalkyl, phenyl, where R(6) also has the meaning of H, R(7) is H or alkyl;   R(2) is 
<
IMAGE
>
     R(11) is (C1-C9)-heteroaryl,   Y is oxygen, -S- or NR(12)-, R(12) is H, (C1-C4)-alkyl; R(3) is defined as R(1), or is alkyl, -X-R(13) where X is oxygen, S, NR(14), R(14) is H, (C1-C3)-alkyl, R(13) is H, (cyclo)alkyl, -CbH2b-R(15) where b is zero to 4 and R(15) is phenyl; R(4) is hydrogen, -OR(16), -NR(16)R(17) or CrF2r+1 where R(16), R(17) independently are hydrogen, (C1-C3)-alkyl, r is 1-4  and their pharmaceutically tolerable salts. The compounds I are outstandingly suitable as antiarrhythmic medicaments having a cardioprotective component for infarct prophylaxis and for infarct treatment and for the treatment of angina pectoris.
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<CLAIMS>
A benzoylguanidine of the formula I 

 
in which : 


R(1)
is hydrogen, F, Cl, Br, I, -NO
2
, -C≡N, 
-X
o
-(CH
2
)
p
- (CF
2
)
q
-CF
3
, R(5)-SO
m
-, R(6)-CO-, 
R(6)R(7)N-CO- or R(6)R(7)N-SO
2
-; 

X
is oxygen, -S- or NR(14); 
m
is zero, 1 or 2; 
o
is zero or 1; 
p
is zero, 1 or 2; 
q
is zero, 1, 2, 3, 4, 5 or 6; 
R(5) and R(6)
are 
(C
1
-C
8
)-alkyl, (C
3
-C
6
)-alkenyl, -C
n
H
2n
-R(8) 
or CF
3
; 

n
is zero, 1, 2, 3 or 4; 
R(8)
is (C
3
-C
7
)-cycloalkyl, or phenyl 
which is unsubstituted or substituted 

by 1 to 3 substituents 
selected from the group consisting  

 
of F, Cl, CF
3
, methyl, methoxy and 
NR(9)R(10);
 
R(9) and R(10) are
 
   H or (C
1
-C
4
)-alkyl; 
 
or 
R(6)
is hydrogen; 
R(7)
is H or (C
1
-C
4
)-alkyl;
 
or 
R(6) and R(7)
together are 4 or 5 methylene groups, of 
which one CH
2
 group can be replaced by 
oxygen, S, NH, N-CH
3
 or N-benzyl; 
R(2)
is 

R(11)
is furanyl, thienyl, pyrrolyl, 
imidazolyl, pyrazolyl, triazolyl, 

tetrazolyl, oxazolyl, isoxazolyl, 
thiazolyl, isothiazolyl, pyridyl, 

pyrazinyl, pyrimidinyl, pyridazinyl, 
indolyl, indazolyl, quinolyl, 

isoquinolyl, phthalazinyl, quinoxalinyl, 
quinazolinyl or cinnolinyl, 

which are linked via C or N and which are 
unsubstituted or substituted by 1 to 3 

substituents selected from the group 
consisting of F, Cl, CF
3
, CH
3
, methoxy, 
hydroxyl, amino, methylamino, 

dimethylamino and benzyl; 
Y
is oxygen, -S- or NR(12)-; 
R(12)
is H or (C
1
-C
4
)-alkyl; 
R(3)
is defined as R(1),
 
or 
R(3)
is (C
1
-C
6
)-alkyl or -X-R(13); 

X
is oxygen, -S- or NR(14); 

R(14)
is 
hydrogen or (C
1
-C
4
)-alkyl;  
 
R(13)
is H, (C
1
-C
6
)-alkyl, (C
3
-C
8
)-cycloalkyl or 
-C
b
H
2b
-R(15) ;
 
b is zero, 1, 2, 3 or 4; 
 
or 


R(13) and R(14)
together are 4 or 5 methylene 
groups, of which one CH
2
 group can be replaced 
by oxygen, S, NH, N-CH
3
 or N-benzyl, 
R(15)
is
 
phenyl which is unsubstituted or substituted 

by 1 - 3 substituents selected from 
the group consisting of F, Cl, CF
3
, 
methyl, methoxy and NR(9)R(10);
 
R(9) and R(10) are
 
   H or (C
1
-C
4
)-alkyl; 
R(4)
is hydrogen, -OR(16), -NR(16)R(17) or C
r
F
2r+1
 ; 

R(16) and R(17)
independently of one another are 
hydrogen or (C
1
-C
3
)-alkyl; 
r
is 1, 2, 3 or 4; 
 
   and pharmaceutically tolerated salts thereof. 
A benzoylguanidine of the formula I as claimed in 
claim 1, in which: 


R(1)
is hydrogen, F, Cl, -C≡N, -CF
3
, R(5)-SO
m
-, 
R(6)-CO-, R(6)R(7)N-CO- or R(6)R(7)N-SO
2
-; 

m
is defined as in claim 1; 
R(5) and R(6)
are
 
(C
1
-C
8
)-alkyl, (C
3
-C
4
)-alkenyl, -C
n
H
2n
-R(8) 
or -CF
3
; 

n
is zero or 1; 
R(8)
is (C
3
-C
6
)-cycloalkyl or phenyl, 
which is unsubstituted or substituted 

as defined in claim 1;
 
where R(6) alternatively has the meaning 

of H, 
R(7)
is H or methyl, 
R(3)
is hydrogen, methyl, cyano, -CF
3
, F or Cl; 
and the other radicals are defined as in claim 1. 
A benzoylguanidine of the formula I as claimed in 
claim 1, in which: 


R(1)
is defined as in claim 2, 

R(5)
is methyl or CF
3
; 
R(6) and R(7)
independently of one another are 
hydrogen or methyl; 
R(2)
is defined as in claim 1; 

R(12) is
hydrogen or methyl; 
R(3)
is defined as in claim 2; 
R(4)
is hydrogen, OH, NH
2
 or CF
3
. 
A benzoylguanidine of the formula I as claimed in 
claim 1, in which: 


R(1)
is defined as in claim 2; 

R(5), R(6) and R(7)
are defined as in claim 3; 
R(2)
is defined as in claim 1 

R(11)
is furanyl, thienyl, pyrrolyl, 
imidazolyl, pyrazolyl, triazolyl, 

tetrazolyl, oxazolyl, isoxazolyl, 
thiazolyl, isothiazolyl, pyridyl, 

pyrazinyl, pyrimidinyl or pyridazinyl; 
which are linked via C or N and which are 

unsubstituted or substituted by 1 to 2 
radicals selected from the group consisting 

of F, Cl, CF
3
, CH
3
, methoxy, 
dimethylamino and benzyl; 
Y
is defined as in claim 1;
 
   R(12) is defined as in claim 3; 
R(3)
is defined as in claim 2; 
R(4)
is defined as in claim 3. 
A benzoylguanidine of the formula I as claimed in 
claim 1, in which: 


R(1)
is defined as in claim 2; 

R(5), R(6) and R(7)
are defined as in claim 3; 
R(2)
is defined as in claim 1, 

R(11)
is pyrrolyl, imidazolyl, pyrazolyl or 
pyridyl,
 
which are unsubstituted or substituted by 

1 to 2 radicals selected from the group 
consisting of F, Cl, CF
3
, CH
3
, methoxy, 
dimethylamino and benzyl; 
Y
is defined as in claim 1;
 
   R(12) is defined as in claim 3; 
R(3)
is defined as in claim 2; 
R(4)
is defined as in claim 3. 
A process for preparing a benzoylguanidine of the 
formula I as claimed in claim 1, which comprises 

reacting a compound of the formula II 

 
in which R(1) to R(4) have the meaning given and
 L 
is a leaving group which can readily be substituted 

nucleophilically, with guanidine. 
Use of a compound I as claimed in claim 1 for preparing 
a medicament for treating arrhythmias. 
Use of a compound I as claimed in claim 1 for preparing 
a medicament for the treatment or prophylaxis 

of cardiac infarction. 
Use of a compound I as claimed in claim 1 for preparing 
a medicament for the treatment or prophylaxis 

of angina pectoris.  
 
Use of a compound I as claimed in claim 1 for preparing 
a medicament for the treatment or prophylaxis 

of ischemic conditions of the heart. 
Use of a compound I as claimed in claim 1 for preparing 
a medicament for the treatment or prophylaxis 

of ischemic conditions of the peripheral and central 
nervous system and of stroke. 
Use of a compound I as claimed in claim 1 for preparing 
a medicament for the treatment or prophylaxis 

of ischemic conditions of peripheral organs and 
limbs. 
Use of a compound I as claimed in claim 1 for preparing 
a medicament for the treatment of conditions 

of shock. 
Use of a compound I as claimed in claim 1 for preparing 
a medicament for employment in surgical 

operations and organ transplantations. 
Use of a compound I as claimed in claim 1 for preparing 
a medicament for the preservation and storage 

of transplants for surgical measures. 
Use of a compound I as claimed in claim 1 for preparing 
a medicament for the treatment of illnesses 

in which cell proliferation represents a primary or 
secondary cause, and thus their use as antiatherosclerotic 

agents, and agents against diabetic 
secondary complications, cancers, fibrotic 

disorders, such as pulmonary fibrosis, hepatic 
fibrosis or renal fibrosis, and prostate 

hyperplasia. 
Use of a compound I as claimed in claim 1 for 
preparing a scientific tool for inhibiting the Na
+
/H
+
 
exchanger, and for diagnosing hypertension and  

 
proliferative disorders. 
A medicine, comprising an effective amount of a 
compound of the formula I as claimed in claim 1. 
</CLAIMS>
</TEXT>
</DOC>
